Podiatrist Loses Drug Rights After Hiding License Suspension Lie
Published Date: 6/13/2025
Notice
Summary
James F. Brown, a podiatrist from Los Angeles, lost his DEA registration because he lied about his suspended medical license and can’t legally handle controlled substances in California. Since he didn’t ask for a hearing, the DEA revoked his registration by default. This means he can no longer prescribe or handle certain drugs, effective immediately.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked Effective July 14, 2025
The DEA revoked Certificate of Registration No. BB7959731 issued to James F. Brown, D.P.M., and the revocation is effective July 14, 2025. As a result, he can no longer prescribe, order, dispense, administer, or possess controlled substances under his DEA registration in California.
Pending Renewal and New Registration Applications Denied
The Order denies any pending applications by James F. Brown to renew or modify DEA registration No. BB7959731 and denies any other pending application of his for additional registration in California. This denial is effective as part of the same Order effective July 14, 2025.
Material Falsification Finding on DEA Renewal
The Agency found that on his June 20, 2023 DEA renewal application, James F. Brown answered "N" to Liability Question 3 despite a prior suspension and related actions by the Podiatric Medical Board of California. The Agency concluded this was a clear, unequivocal, and convincing material falsification and used that finding as a basis for revocation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-10741 — TriplePoint Venture Growth BDC Corp., et al.
TriplePoint Venture Growth BDC Corp. and its related companies want permission to team up and invest together in the same businesses, which usually isn’t allowed. This change could help them share opportunities and grow investments more smoothly. If you want to speak up, you have until July 7, 2025, to ask for a hearing before the SEC decides.
Next: 2025-10743 — Silicon Metal From Angola, Australia, Laos, Norway, and Thailand
The U.S. is checking if silicon metal imports from Angola, Australia, Laos, Norway, and Thailand are hurting American businesses by being sold too cheaply or getting unfair government help. The investigation is moving to the final phase, which could lead to new rules or tariffs to protect U.S. companies. If you’re involved in this trade, keep an eye out for updates soon that might affect prices and import rules.